In this study, we investigated the mechanisms by which caveolin-1 (CAV) inhibits increases in permeability induced by platelet activating factor (PAF) and elucidated the relationship between the endothelial intracellular Ca 2þ concentration ([Ca 2þ ] i ) and CAV in regulating endothelial nitric oxide synthase (eNOS) activity and microvessel permeability in intact microvessels.
In this study, we investigated the mechanisms by which caveolin-1 (CAV) inhibits increases in permeability induced by platelet activating factor (PAF) and elucidated the relationship between the endothelial intracellular Ca 2þ concentration ([Ca 2þ ] i ) and CAV in regulating endothelial nitric oxide synthase (eNOS) activity and microvessel permeability in intact microvessels.
Methods and results
Experiments were conducted in individually perfused mesenteric venules in Sprague-Dawley rats. Permeability was determined by measuring hydraulic conductivity (Lp). Endothelial [Ca 2þ ] i and nitric oxide (NO) production were measured in fura-2-and DAF-2-loaded microvessels. Perfusion of the CAV scaffolding domain, AP-CAV, at 1 mM for 30 min did not affect PAF-induced increases in endothelial [Ca 2þ ] i but significantly attenuated PAF-induced NO production from 143 + 2 to 110 + 3% of control fluorescence intensity (FI). The PAF-induced Lp increase was correlatively reduced from a mean peak value of 7.5 + 0.9 to 1.9 + 0.5 times that of the control. Increasing extracellular [Ca 2þ ] that potentiated PAF-induced peak [Ca 2þ ] i from 500 to 1225 nM augmented NO production to 193 + 13%
and further increased Lp to 17.3 + 1.6 times the control value. More importantly, enhanced Ca 2þ influx restored the reduced NO production and Lp by AP-CAV with NO FI at 149% and Lp at 7.7 + 1.1 times the control value.
Conclusion
Our results indicate that eNOS inhibition and reduced NO production contribute to the inhibitory action of AP-CAV on PAF-induced increases in permeability. CAV and endothelial [Ca 2þ ] i antagonistically regulate eNOS activity in intact microvessels, and the level of produced NO is the key determinant of the degree of permeability increases during inflammation.
Introduction
Increases in microvessel permeability occur in a variety of cardiovascular diseases, often resulting in tissue oedema and organ dysfunction. A better understanding of the mechanisms that regulate microvascular permeability is crucial for defining the pathogenesis of many disease conditions and aiding in the development of novel therapeutic approaches. Nitric oxide (NO), in addition to its role as a potent vasodilator regulating vascular tone, blood pressure, and local blood flow, has also been recognized as an important intrinsic modulator of microvessel permeability. Early studies in whole vascular beds reported that the inhibition of NOS increased basal levels of permeability and potentiated agonist-induced permeability increases, indicating that NO plays a protective role for vascular walls. 1, 2 In contrast, studies from our laboratory and others have demonstrated that pharmacological NOS inhibitors attenuated agonist-induced increases in microvessel permeability. 3 -6 Although this paradox remains to be resolved, recent evidence has suggested that the physiological functions of NO are modulated under inflammatory conditions. Whereas basal levels of NO are anti-inflammatory due to its roles in preventing leucocyte adhesion and platelet aggregation, inflammatory stimuli-induced NO exerts pathological effects, including increases in microvessel permeability. 3,7 -11 However, owing to the non-specificity of NOS inhibitors, previous studies have been unable to determine the NOS isoforms responsible for the increased microvessel permeability under inflammatory conditions. The important role of endothelial nitric oxide synthase (eNOS) activation during inflammation has only been recognized recently with the discovery of the scaffolding domain of caveolin-1 (CAV) that directly interacts with eNOS, and the use of Antennapedia homeodomain (AP) fusions to facilitate CAV uptake by living cells. 7 -9,11,12 The application of AP-CAV suppressed tissue oedema and vascular leakage in whole animals 8, 9 and prevented permeability increases in individually perfused microvessels. 7, 11 These in vivo studies implicate the involvement of eNOS activation under inflammatory conditions. Endothelial NOS is markedly enriched in caveolae and co-localizes with CAV. 10, 13 Cell culture studies have shown that the over-expression of caveolin significantly attenuated eNOS activity and that purified calmodulin (CaM) reverses this inhibition, suggesting that CAV and Ca 2þ / CaM counteractively regulate eNOS activity. 14, 15 However, the direct measurement of NO with exogenously applied CAV in intact microvessels has not been explored, and the antagonistic relationship between CAV and Ca 2þ /CaM in regulating stimuli-induced eNOS activity in vivo remains unidentified. In addition, cell-culture studies reported that AP-CAV markedly reduced thrombin-induced Ca 2þ influx, 16 an essential signal for permeability increases. 17, 18 Considering the proximity of CAV to the signalling machinery regulating Ca 2þ entry within caveolae, 19 it is possible that the inhibitory role of AP-CAV in microvessel permeability is due to its inhibition on agonist-induced Ca 2þ entry.
This study aims to address these questions by investigating whether the inhibitory role of AP-CAV in platelet activating factor (PAF)-induced permeability increases is due to its inhibition of eNOS, and further elucidate the relationship between endothelial [Ca 2þ ] i and CAV in regulating eNOS activity and microvessel permeability in intact microvessels. Experiments were designed to closely maintain in vivo physiology by using individually perfused venular microvessels in rat mesenteries. 
Fluorescence imaging of endothelial NO production
Endothelial NO was quantified at cellular levels in individually perfused microvessels using fluorescence imaging and 4,5-diaminofluorescein diacetate (DAF-2 DA), a fluorescent indicator for NO. The experimental rigs were the same as those for the Ca 2þ measurements, except that a cooled, charge-couple device camera (ORCA; Hamamatsu) was used for image acquisition. In each experiment, a venular microvessel was perfused with albumin-Ringer solution containing DAF-2 DA (5 mM) for 45 min, followed by albumin-Ringer perfusion for 10 min before acquiring the control images. Images under control conditions and after exposure to testing agents were acquired from the same group of endothelial cells in each vessel using identical instrument settings. At the end of each experiment, the NO donor, sodium nitroprusside (SNP, 50 mM), was applied to the superfusate to examine the loading status. Selected regions of interest (ROIs) along the vessel wall were used to measure the FI DAF . Each ROI covers the area of one endothelial cell, as indicated by the fluorescence outline upon the addition of SNP. The maximum stimulated FI DAF (at plateau level) was compared with the control FI DAF measured in the same ROI and expressed as (FI/FI 0 ) Â 100, in which FI is the FI DAF after stimulation and FI 0 is the control FI DAF . The criterion for a responsive cell was a significant increase in FI DAF relative to the control in each ROI. The increase in FI DAF in each vessel was the mean of the FI DAF changes from all the responsive cells. 20 NO production rate is derived from differential conversion of the cumulative DAF-2 FI. The details have been described elsewhere 20 and in Supplementary material online.
Solutions and reagents
Mammalian Ringer solution 17 was used for the experiments. The high Ca 2þ solution has the same composition as that in normal Ringer solution except that CaCl 2 was increased from 2 to 10 mM. All the perfusates contained BSA (10 mg/mL). AP-CAV, the fusion peptide of the CAV scaffolding domain with AP, the Antennapedia internalization sequence from Drosophila AP, and the AP-CAV-X, which is the fusion peptide of scrambled CAV with AP were synthesized by Tufts University. 8, 11 The stock solutions were prepared with 100% DMSO and each final concentration was achieved by .1:1000 dilution with albumin-Ringer solution.
See Supplementary material online for details.
Regulation of eNOS activity and microvessel permeability
Data analysis and statistics
All values are means + SE. Paired t-test was used for paired data analysis. ANOVA was used to compare data between groups. A probability value of P , 0.05 was considered statistically significant. In summary figures, asterisk (*) indicates a significant increase from the negative or positive control, and dagger ( †) indicates a significant decrease from the positive control.
Results

AP-CAV attenuates PAF-induced increases in Lp
We first examined PAF-induced increases in Lp in the absence of AP-CAV application in six microvessels. The mean control Lp was 1.6 + 0. observed upon PAF (10 nM) addition. The peak Lp, occurred within 10 min of PAF perfusion, was 7.5 + 0.9 times that of the control and then fell to 2.9 + 0.3 times the control value in 20 min. Figure 1A shows a representative time course of PAF-induced Lp changes.
Our previous study demonstrated that perfusion of mesenteric venules with AP-CAV at 10 mM for 2 h effectively attenuated PAF-induced increases in Lp. 11 However, we do not know whether that is the minimum amount of AP-CAV needed to compete with PAF-induced increases in endothelial [Ca 2þ ] i . To quantitatively evaluate the competing roles of CAV and endothelial [Ca 2þ ] i in regulating microvessel permeability, we reduced the applied peptide concentration and perfusion time to identify the minimum amount of CAV required to inhibit PAF-induced eNOS activation and Lp increases. We first found that a 30 min perfusion with 0.1 mM AP-CAV had no effect on PAF-induced Lp increases (n ¼ 2). Then we increased the AP-CAV concentration to 1 mM and kept the perfusion time at 30 min. The results from five microvessels showed that this combined concentration and perfusion time did not significantly affect the baseline Lp (1.5 + 0.2 vs.
, but sufficiently attenuated PAF-induced peak Lp from 7.5 + 0.9 to 1.9 + 0.5 times that of the control (P , 0.01).
The specificity of the AP-CAV effect was examined in another four vessels using a scrambled CAV peptide, AP-CAV-X. Perfusion of AP-CAV-X (1 mM) for 30 min showed no effect on the baseline Lp (1.2 + 0.1 vs. Figure 1B shows the comparison of PAF-induced increases in Lp with either AP-CAV or AP-CAV-X. Figure 5C summarizes the results. Figure 2A and B shows a direct comparison of PAF-induced endothelial [Ca 2þ ] i in the absence or presence of AP-CAV. Figure 5A summarizes the results. The effect of AP-CAV on PAF-induced NO production was examined in DAF-2-loaded vessels using fluorescence imaging. PAF-induced NO production in the absence of AP-CAV was quantified in 78 endothelial cells, (ROIs, 12-20 per vessel) in five microvessels, of which 83 + 2% were responsive cells that showed significant increases in FI DAF relative to the control. The mean maximum FI DAF measured at plateau from all responsive cells was 143 + 2% of the baseline. The effect of AP-CAV on PAF-induced NO production was examined in another five microvessels (total 54 ROIs, 9-13 per vessel). When PAF was applied to AP-CAV (1 mM) pre-perfused vessels, the number of responsive cells decreased to 34 + 18% and the mean FI DAF of all responsive cells was only 110 + 3% of the baseline level. Figure 2C shows the time-dependent cumulative FI DAF changes and the NO production rate in the presence or absence of AP-CAV. Figure 4A presents the images from two representative experiments. Figure 5B summarizes the results. Regulation of eNOS activity and microvessel permeability FI DAF , and the mean maximum FI DAF from all the cells was 193 + 12% relative to the control level. This was significantly higher than PAF-induced NO under normal [Ca 2þ ] o (83% responsive cells with mean FI DAF at 143%, P , 0.01). Figure 3B shows the time-dependent FI DAF changes and the calculated NO production rate from two of the experiments under each condition. Figure 5B presents ] o (7.5-fold, P , 0.01). Figure 3C shows the comparisons of the Lp increases from two of the experiments. Figure 5C summarizes the Lp results. was potentiated by high Ca 2þ solutions. Figure 4B shows representative images of two individual experiments. After AP-CAV (1 mM) perfusion for 30 min, the PAF-induced mean maximum FI DAF with high Figure 4C shows the differences in PAF-induced NO under these two experimental conditions. Figure 5B presents the summarized results.
AP-CAV inhibited PAF-induced
Enhanced endothelial [Ca
The results shown above demonstrate that AP-CAV has no effect on PAF- ). However, when each vessel was exposed to high Ca 2þ solution and PAF, the mean peak Lp PAF /Lp control was only 7.7 + 1.1, which is a marked attenuation from the peak Lp measured with high [Ca 2þ ] o in the absence of AP-CAV (17.3 + 1.6 times the control value, P , 0.05). These results indicate that the reduced NO by AP-CAV determines the degree of the permeability increase. Figure 4D shows one of the experiments. Figure 5C summarized the results of Lp. A direct correlation between the level of endothelial NO production and the magnitude of Lp increases under four different experimental conditions is plotted in Figure 5D that illustrates a linear relationship.
Discussion
This study demonstrates the molecular mechanisms of eNOS regulation and NO-dependent changes in microvessel permeability in intact vessels. The important findings are that (i) CAV and endothelial [Ca 2þ ] i antagonistically regulate eNOS activity and their overall balance determines the level of NO production in intact microvessels and (ii) eNOS activation downstream from Ca 2þ signalling is essential for increases in microvessel permeability during acute inflammation. Regulation of eNOS activity and microvessel permeability experimental conditions demonstrated that AP-CAV inhibits PAF-induced permeability increases via its direct inhibition of eNOS and NO production. By modulating the relative magnitude of intracellular CAV and [Ca 2þ ] i , we provided the first quantitative evidence in intact microvessels that under stimulated conditions CAV and Ca 2þ /CaM complexes antagonistically regulate eNOS activity and NO production. Most importantly, the results indicate that eNOS activity is the key determinant of permeability increases under stimulated conditions. Although the application of pharmacological NOS inhibitors has been shown to attenuate permeability increases induced by a variety of inflammatory mediators for more than a decade, 3 -5,20,23,24 the role of eNOS in regulating microvessel permeability has only been demonstrated recently with the use of a membrane-permeable, eNOS-specific binding domain of CAV (AP-CAV). 7, 8, 11, 12 Fluorescence images and electron-microscopic micrographs have illustrated that the AP-facilitated delivery of CAV through single vessel perfusion is specifically localized within the endothelial caveolae. 11 The actions of AP appear to be mediated through its direct interaction with membrane phospholipids, which are receptor-independent and non-endocytotic, even though detailed mechanisms have not been well defined. 25 The measurements of hydraulic conductivity in individually perfused microvessels, which enable the changes in permeability to be separated from haemodynamic factor-induced flux changes, demonstrated that AP-CAV in endothelial cells significantly attenuates PAF-induced increases in microvessel permeability. 7, 11 Our present study provides molecular mechanisms for CAV-mediated inhibition of permeability increases in intact microvessels. It has been well established that agonist-induced Ca 2þ influx is a necessary initial signal for permeability increases. 17, 26 Studies using genetic approaches showed that CAV is required for agoniststimulated Ca 2þ entry into vascular endothelial cells and may play regulatory roles for Ca 2þ influx. 13 Cell-culture studies reported that AP-CAV reduced thrombin and thapsigargin-induced Ca 2þ influx by direct interaction with a transient receptor-potential cation channel in human pulmonary artery endothelial cells. 16 Our results demonstrated that AP-CAV has no effect on PAF-induced increases in endothelial [Ca 2þ ] i under both normal and high [Ca 2þ ] o conditions, yet significantly reduces PAF-induced NO production, indicating that the inhibition of PAF-induced permeability by AP-CAV is due to its inhibition of eNOS activity rather than of Ca 2þ influx. These results are consistent with our previous study using the NOS inhibitor L-NMMA. 20 The discrepancies between our results and the cultured cell studies 16 These results indicate that the applied AP-CAV antagonistically competes with the activated Ca 2þ /CaM in regulating eNOS activity and the overall balance between these two antagonistic regulatory proteins determines the level of NO production in stimulated intact microvessels. Agonist-induced initial Ca 2þ influx has been shown to correlate directly with the magnitude of permeability increases under most conditions. 26, 28 This study demonstrated that the magnitude of the changes in microvessel permeability are directly correlated with the level of NO rather than with endothelial [Ca 2þ ] i ( Figure 5D ). PAF and other inflammatory mediator-induced increases in microvessel permeability have been recognized as the results of endothelial gap formation, 18, 29, 30 which has been attributed to the contractile mechanism of actin -myosin interaction and/or the redistribution of adherens junctions between endothelial cells. 30, 31 This study indicates that CAV and endothelial [Ca 2þ ] i counteractively regulate eNOS activity in intact microvessels and that eNOS activation is a critical step resulting in increased microvessel permeability during acute inflammation. The exact processes and signalling pathways between the increased intracellular NO and endothelial gap formation, however, remain to be identified. On the basis of the linear relationship between the magnitude of NO and Lp changes we observed at vessel level ( Figure 5D ), the variations of NO production among endothelial cells might directly associate with the heterogeneity of vascular leakages in vascular walls in response to inflammatory stimuli. Further simultaneous quantifications of endothelial [Ca 2þ ] i , NO, and endothelial gap formation at the individual cell level in intact microvessels would provide detailed cellular mechanisms for permeability regulation. Furthermore, eNOS activity, in addition to being regulated by CAV and Ca 2þ /CaM, was also reported to be regulated by other proteins or via Ca 2þ -independent activation pathways, such as serine, threonine, or tyrosine phosphorylation. Although the regulation of eNOS by CAV and Ca 2þ /CaM under inflammatory conditions has been well documented by previous and the present studies, a heterogeneous picture of eNOS regulation and signalling is now emerging, and how these distinct pathways affect vascular functions remain to be investigated.
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